Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
AstraZeneca Grabs All Global Fasenra Rights in Expanded Pact with Kyowa Kirin
Kyowa Hakko Kirin said on March 25 that it has extended its accord with AstraZeneca, granting it exclusive rights to Fasenra (benralizumab) for all indications beyond COPD and asthma in Asia including Japan. The UK firm now has worldwide rights…
To read the full story
Related Article
- AZ Gets Asian Rights to Kyowa Kirin’s Benralizumab
March 27, 2017
- AZ to Commercialize Kyowa Kirin’s COPD Drug in Japan
October 31, 2016
- Kyowa Kirin Grants AZ Option Rights to Commercialization of Benralizumab in Japan
July 17, 2015
BUSINESS
- MSD Launches RSV Antibody Enflonsia in Japan without NHI Listing
August 24, 2026
- Sumitomo Pharma Eyes Global Position as Adjuvant Supplier
August 24, 2026
- Oncolys’ Oncolytic Virus Telomelysin Hits Japan Market
August 24, 2026
- Sobi’s Still’s Disease Drug Kineret Now Available in Japan
August 24, 2026
- MSD Files Welireg-Keytruda Combo in Japan for Adjuvant RCC
August 24, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…